A Phase 2 Study of E6005 in Patients With Atopic Dermatitis
- Registration Number
- NCT01461941
- Lead Sponsor
- Organon and Co
- Brief Summary
The purpose of this study is to evaluate the efficacy and safety profiles of E6005 ointment in patients with atopic dermatitis compared to vehicle. The pharmacokinetic profile after topical application of E6005 is also assessed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 78
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Drug: 0.2% E6005 ointment E6005 - Drug: 0.0% E6005 ointment (vehicle) E6005 ointment (vehicle) -
- Primary Outcome Measures
Name Time Method Changes of pruritus score from baseline From baseline through 12 weeks Changes of eczema area and severity from baseline From baseline through 12 weeks
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does E6005 target in atopic dermatitis treatment?
How does E6005 ointment compare to standard-of-care topical corticosteroids in atopic dermatitis?
Are there specific biomarkers associated with E6005 response in atopic dermatitis patients?
What adverse events were observed in the E6005 phase 2 trial for atopic dermatitis?
What are the pharmacokinetic properties of E6005 after topical application in atopic dermatitis?